US equities |
MU $1,086.94 ▲+3.96% NVDA $236.89 ▼-0.98% SNDK $1,724.15 ▲+3.84% SPCX $167.78 ▼-2.41% AMD $645.68 ▼-0.58% INTC $112.67 ▲+0.15% TSLA $376.75 ▼-1.03% AAPL $336.88 ▲+0.97%
FinancialContent

eXoZymes Inc. - Common Stock (NQ:EXOZ)

5.550 +0.030 (+0.54%)
Delayed Quote Updated: 1:15 PM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about eXoZymes Inc. - Common Stock

< Previous 1 2 Next >
Water Tower Research Publishes Initiation of Coverage Report on eXoZymes, Inc., "Converting Cell-Free Science into a Scalable and Repeatable Commercial Opportunity"
October 2, 2026, ST. PETERSBURG, FL – Water Tower Research (www.watertowerresearch.com) has published an Initiation of Coverage Report on eXoZymes, Inc. (NASDAQ: EXOZ) titled, “Converting Cell-Free... 
Via TheNewswire.com
Topics Initial Public Offering
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Gainers EXoZymes (NASDAQ:EXOZ) stock increased by 7.5% to $7.18 during Wednesday's after-market session. The market value of their outstanding shares is at $58.5 million. AEON Biopharma (AMEX:AEON)... 
Via Benzinga
News headline image
eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT
Program expected to commence in Q4 2026 and establish a roadmap for larger-scale production in 2027 
From eXoZymes
Via ACCESS Newswire
News headline image
Investor Summit | MicroCap Opportunities to Watch - August 26
From Investor Summit Group
Via ACCESS Newswire
News headline image
eXoZymes Provides Fourth Quarter and Full Year 2025 Update
Via ACCESS Newswire
News headline image
Earnings Scheduled For November 13, 2025 ↗
 
Via Benzinga
News headline image
eXoZymes Q2 Earnings Call Highlights ↗
eXoZymes (NASDAQ:EXOZ) outlined progress toward commercializing its NCT program, including a reported tenfold increase in process productivity versus its March pilot campaign, while management said it... 
Via MarketBeat
Topics Earnings
News headline image
eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today
From eXoZymes
Via ACCESS Newswire
News headline image
eXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets
From eXoZymes
Via ACCESS Newswire
News headline image
eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026
From eXoZymes
Via ACCESS Newswire
News headline image
eXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing
From eXoZymes
Via ACCESS Newswire
News headline image
Q2 Virtual Investor Summit Presentations Now Available On Demand
From Investor Summit Group
Via ACCESS Newswire
News headline image
eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery
From eXoZymes
Via ACCESS Newswire
News headline image
eXoZymes Inc. Announces Closing of $6 Million Public Offering
From eXoZymes
Via ACCESS Newswire
News headline image
eXoZymes Inc. Announces Pricing of Public Offering of Common Stock and Warrants
Via ACCESS Newswire
News headline image
eXoZymes Announces Graduation from Shell GameChanger(TM) Accelerator Powered by NLR (GCxN) Program
Via ACCESS Newswire
News headline image
eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast
Via ACCESS Newswire
News headline image
eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026
Via ACCESS Newswire
News headline image
Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes' Technology and Scalability
Via ACCESS Newswire
News headline image
eXoZymes' CCO Damien Perriman to Present a NCT Solution at Next Week's MISTA Symposium
Via ACCESS Newswire
News headline image
With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Drive Platform Leverage and Long-Term Value Creation
Via ACCESS Newswire
News headline image
eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot Run
Via ACCESS Newswire
News headline image
eXoZymes Achieves 100× Scale-up of NCT Production Using Exozymes, Demonstrating Near-perfect Feedstock Conversion
Via ACCESS Newswire
News headline image
eXoZymes Provides Third Quarter 2025 Update at 5PM EST Today
Via ACCESS Newswire
News headline image
eXoZymes Announces Cell-Free Biomanufacturing Pioneer, Tyler Korman, As CSO & Amy Lunzer as Chief of Staff
Via ACCESS Newswire
News headline image
eXoZymes to Host Third Quarter 2025 Update on Thursday November 13, 2025, at 5PM EST
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
CEO of eXoZymes on 'AI in Life Sciences' panel at the Beryl Elites' Investment Conference
Via ACCESS Newswire
News headline image
CEO of eXoZymes to Present at Spartan Capital Securities' Second Annual Investor Conference
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
< Previous 1 2 Next >